KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) Invested Capital (2017 - 2025)

Historic Invested Capital for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $39.8 million.

  • Co-Diagnostics' Invested Capital fell 3755.76% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.8 million, marking a year-over-year decrease of 3755.76%. This contributed to the annual value of $54.3 million for FY2024, which is 3685.66% down from last year.
  • As of Q3 2025, Co-Diagnostics' Invested Capital stood at $39.8 million, which was down 3755.76% from $41.1 million recorded in Q2 2025.
  • Co-Diagnostics' 5-year Invested Capital high stood at $147.7 million for Q1 2022, and its period low was $39.8 million during Q3 2025.
  • Its 5-year average for Invested Capital is $91.4 million, with a median of $87.4 million in 2021.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 29600.56% in 2021, then crashed by 4317.72% in 2025.
  • Co-Diagnostics' Invested Capital (Quarter) stood at $134.5 million in 2021, then fell by 14.84% to $114.5 million in 2022, then dropped by 24.89% to $86.0 million in 2023, then tumbled by 36.86% to $54.3 million in 2024, then decreased by 26.67% to $39.8 million in 2025.
  • Its Invested Capital stands at $39.8 million for Q3 2025, versus $41.1 million for Q2 2025 and $47.9 million for Q1 2025.